and leiomyosarcoma. There is a tendency for certain types of sarcoma to originate from specific anatomic sites, such as the abdomen for leiomyosarcoma or the extremities for liposarcoma and undifferentiated pleomorphic sarcoma [2] . Surgical resection is the treatment of choice for localized disease, with radiation given as first-line therapy for unresectable cases.
Nonetheless, 50% of high-grade tumors tend to recur [3] . For decades, treatment options for soft tissue sarcoma have been limited to doxorubicin and/or ifosfamide, and the outcome for metastatic disease is poor, with an estimated median survival of 8-13 months, as reported from results of randomized studies conducted over the last 20 years [4] [5] [6] [7] . Targeted therapies have recently come of age for soft tissue sarcoma, with the USFDA approval of pazopanib for locally advanced unresectable or metastatic soft tissue sarcoma with the exception of liposarcoma in 2012. Approval was based on the results of a randomized placebo-controlled Phase 3 (PALETTE) trial showing a significant, but modest, benefit in progression-free survival (PFS) for patients treated with pazopanib [8] . The approval of trabectedin in the USA in late 2015 shows promise for further improving the quality of life and progression-free survival of patients with soft tissue sarcoma.
Trabectedin is a natural alkaloid derived from the Caribbean tunicate, Ecteinascidia turbinata. It has multiple complex mechanisms of action [2, [9] [10] [11] [12] [13] and consequently the potential for extensive clinical applications. Further, several features of trabectedin's clinical performance differentiate it from other oncologic agents. These include prolonged tumor growth stabilization, favorable outcomes in sarcomas with genetic mutations, durability of responseeven upon treatment reinstitution after interruption of therapy, and absence of cumulative toxicity [14] . This article reports on the critical stages of drug development of trabectedin in the US and worldwide and provides perspectives on its future as a uniquely effective oncologic agent for soft tissue sarcomas and other solid malignancies.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
CRITICAL STAGES OF TRABECTEDIN DRUG DEVELOPMENT

Preclinical Studies
Trabectedin, derived from the marine tunicate, Ecteinascidia turbinata, has multiple complex mechanisms of action. In preclinical studies, trabectedin has been shown to bind to the N2 amino group of guanine residues in the minor groove of the DNA double helix and cause double-strand breaks [2, 9, 10] . Second, trabectedin interrupts the cell cycle, causes apoptosis of cancer cells and downregulates abnormal transcription factor expression such as FUS-CHOP or EWS-CHOP [10] . Third, trabectedin inhibits cytokine release by monocytes and macrophages in the tumor microenvironment via its direct cytotoxic effects on tumor-associated macrophages [11, 12] . This drug effect on the tumor microenvironment is deemed critically important in cancer therapy because of the resultant inhibition of neoangiogenesis and the metastatic potential of cancer cells [13] .
Clinical Studies
Efficacy Studies [27] . The biologic half-life of trabectedin ranged from 27 to 89 h in pharmacokinetic studies [15, 18, 19] , depending on the mode of administration and infusion schedule. The terminal half-life calculated using data from 14 Phase 1 and Phase 2 studies using non-linear mixed effects models was longer, in the range of 175 h [27] .
Of the five Phase 1 studies using trabectedin and one other chemotherapeutic agent, the most promising combination regimen in advanced soft tissue sarcomas (STS) and breast cancer was trabectedin with doxorubicin, with an overall response rate (ORR) of 18%, SD of 56%, and disease control rate (DCR) of 74% [26] . 
Expanded Access Program
The expanded access program for advanced soft tissue sarcomas following failure of prior chemotherapy enrolled 1895 patients worldwide (Table 1) [44] . Analysis of the data revealed that patients with leiomyosarcoma and liposarcoma had a higher ORR (6.9% vs. 4%, respectively) and significantly longer OS (16.2 vs. 8.4 months, respectively) than all other histological subtypes. Patient enrollment has continued beyond this publication.
Toxicity Studies
The adverse events reported in the Phase 3 trial of trabectedin vs. dacarbazine in leiomyosarcoma and liposarcoma patients who had failed at least one anthracycline-based regimen and one of another chemotherapeutic agent are listed in the USFDA Product Information document [45] . The most common adverse reactions occurring in greater than 10% of patients, and at a higher incidence than the control arm receiving dacarbazine, include nausea in 75%, fatigue in 69%, vomiting in 46%, constipation and decreased appetite in 37%, and diarrhea in 35%. Less common adverse reactions were dyspnea and headache in 25%, arthalgia and insomnia in 15%, and myalgia in 12%. Grade 3-4 adverse reactions were uncommon (\10%). The most common laboratory abnormalities include anemia in 96%, increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase levels in 90, 84, and 70%, respectively, neutropenia in 66%, hypoalbuminemia in 63%, thrombocytopenia in 59%, increased creatine phosphokinase in 33%, and hyperbilirubinemia in 13%. Among the common grade 3-4 adverse events ([10%) were neutropenia in 43%, thrombocytopenia in 21%, anemia in 19%, and increased ALT and AST levels in 31% and 17%, respectively.
An important factor in reducing toxicity is the use of dexamethasone as pre-medication before starting trabectedin infusion. In a previous study by Grosso et al., the incidence of grade 3-4 liver enzyme elevation, neutropenia, and thrombocytopenia fell to 3, 10, and 0%, respectively, in patients who received routine antiemetic prophylaxis with steroids on day 0 and possibly on day ?1, compared with 70, 39, and 35%, respectively, in the group who received dexamethasone prophylaxis 4 mg PO BID the day before trabectedin infusion (p = 0.0001) [46, 47] . 
TRABECTEDIN APPLICATIONS IN THE CLINIC
